Project Details
| Status | Active |
|---|---|
| Effective start/end date | 01/29/24 → 02/1/29 |
Funding
- Sanofi US Services Incorporated: $58,529.26
A 52-week Randomized, Double-Blind, Placebo-Controlled, Multi-center Phase 2b Study with a 52-week Blinded Extension Assessing Safety and Efficacy of Frexalimab, a DC40L-Antagonist Monoclonal Antibody, for Preservation of Pancreatic...
- Quattrin, Teresa (PI)
Project: Research